Recent research has explored the use of GLP-1 RAs as an adjunctive pharmacotherapy for individuals with T1D.14,15 Obesity, accompanied by insulin resistance, is prevalent not only in T2D but also in many individuals with T1D.16, , , -20 Although GLP-1 RAs are not FDA-approved for T1D, several providers have been prescribing these medications off-label, especially for adults. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.